Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.

  • Revenue in DKK (TTM)188.29bn
  • Net income in DKK61.13bn
  • Incorporated1931
  • Employees57.09k
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
NOVO B:CPH since
Forma Therapeutics Holdings IncDeal completed01 Sep 202201 Sep 2022Deal completed40.85%1.11bn
Marinus Pharmaceuticals Inc-Priority Review VoucherAnnounced14 Jul 202214 Jul 2022Announced37.77%110.00m
Data delayed at least 15 minutes, as of May 31 2023 15:59 BST.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
Bayer AG376.03bn22.62bn390.86bn101.74k17.281.285.501.043.093.0951.3941.600.40261.673.46498,071.402.44-1.113.30-1.4559.5458.986.05-3.040.75874.950.5135--15.107.70315.005.024.50-2.72
GSK plc250.50bn37.38bn483.53bn69.40k12.444.758.001.931.103.647.522.890.39231.513.84419,092.206.456.399.8210.4270.4269.5516.4415.900.6949.710.648993.3718.74-0.577851.7310.270.5035-5.53
Sanofi SA344.08bn62.24bn886.68bn91.57k14.19--11.322.586.656.6536.84--------504,504.60--5.80--7.0269.9368.4918.2417.00--102.64--59.8415.864.6234.5217.282.393.28
Novartis AG361.61bn48.73bn1.52tn103.00k29.633.8817.374.202.942.9421.7822.480.43912.036.02464,186.405.929.097.9511.7771.0970.9813.4823.680.793112.260.358659.94-2.153.60-71.05-1.493.093.79
AstraZeneca plc304.17bn32.64bn1.53tn83.50k47.096.1521.205.022.432.4322.6418.600.44521.354.62422,959.704.782.636.313.6280.6378.9910.746.350.69596.820.468187.0718.5314.572,835.716.639.681.13
Roche Holding AG484.71bn95.14bn1.80tn103.61k18.758.2213.563.7215.3615.3678.3235.030.70132.275.65610,743.8015.0016.2125.3125.3370.7571.0721.3822.620.925619.250.441959.330.76433.49-10.837.262.632.74
Novo Nordisk A/S188.29bn61.13bn1.92tn57.09k41.5231.4228.2910.1826.8826.8882.7135.520.84221.294.343,461,659.0027.3429.8355.6758.5884.2283.7632.4732.860.669416.840.242145.8825.689.6416.277.8111.279.57
Data as of May 31 2023. Currency figures normalised to Novo Nordisk A/S's reporting currency: Danish Krone DKK

Institutional shareholders

16.97%Per cent of shares held by top holders
HolderShares% Held
Capital Research & Management Co. (World Investors)as of 04 May 202366.35m3.86%
The Vanguard Group, Inc.as of 05 May 202343.49m2.53%
Norges Bank Investment Managementas of 31 Dec 202243.41m2.53%
BlackRock Fund Advisorsas of 04 May 202328.86m1.68%
Alecta Pension Insurance Mutualas of 31 Dec 201927.09m1.58%
Fundsmith LLPas of 30 Jun 202221.22m1.24%
Capital Research & Management Co. (Global Investors)as of 04 May 202318.31m1.07%
BlackRock Investment Management (UK) Ltd.as of 30 Apr 202316.77m0.98%
Fidelity Management & Research Co. LLCas of 31 Mar 202313.38m0.78%
BlackRock Advisors (UK) Ltd.as of 04 May 202312.57m0.73%
More ▼
Data from 31 Dec 2022 - 31 Mar 2023Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.